Plants, products and canine evidence—
understood clearly.

Phytotherapy, pharmacognosy and botanical medicine

Phytotherapy is the study and therapeutic context of medicines derived from plants. Pharmacognosy is the wider natural-products discipline that asks what the material is, where it came from, how it was prepared, which constituents characterize it, how its quality is checked and what biological evidence exists. Veterinary botanical medicine applies those questions to animals. These terms overlap, but they are not interchangeable with folk use, retail supplement sales or the assumption that a natural origin guarantees benefit.

A pharmacognostic description begins before any discussion of effects. It records the accepted scientific name, family, plant part, preparation, extraction or manufacturing method, analytical markers, route and finished-product composition. A turmeric rhizome powder, a curcuminoid extract and a fortified diet can all contain material from Curcuma longa while remaining different interventions. The botanical name tells us the source; it does not finish the product description.

Traditional use belongs in the course as historical and cultural context. It can explain why a plant attracted interest and can generate research questions. It does not, by itself, establish that a preparation is effective in dogs. The evidence grade therefore belongs to a precise claim, not to the age or popularity of the tradition.

The complete canine evidence unit

The course uses one sentence as its intellectual backbone: plant identity + plant part + preparation + extraction or manufacturing method + route + reported research exposure + canine population + comparator + outcome. Each term closes a common loophole in botanical marketing. If the part is unknown, leaf and root evidence may be merged. If the preparation is missing, a whole herb may be treated as equivalent to an enriched extract. If the comparator or outcome disappears, improvement from baseline can be mistaken for a treatment effect.

Consider the claim “turmeric helps dogs with arthritis.” A researchable version might ask whether a named fortified diet containing a characterized curcuminoid extract and other ingredients, given orally to client-owned dogs with diagnosed osteoarthritis, differs from a matched control diet on owner-reported pain and objective ground-reaction-force outcomes over the study period. That reconstructed question is less catchy, but it reveals what the study can and cannot answer.

The phrase reported research exposure is used instead of dose in learner-facing evidence tables. A paper may need an amount to be understood, especially in pharmacokinetics, but the reported amount remains part of that experiment. It is not automatically a suitable amount for another formulation, another dog or home use.

Dogs are neither small humans nor one uniform population

Human botanical literature can help identify chemistry, plausible mechanisms and research questions. It is indirect evidence for canine clinical benefit. Dogs differ from humans in physiology, metabolism, diet, body composition, disease patterns and product exposure. Even within dogs, a healthy laboratory population does not fully represent an older companion dog with osteoarthritis, liver disease and several concurrent medicines.

Transferability must therefore be argued, not assumed. A study of healthy dogs may describe absorption and short-term tolerance but cannot establish effectiveness in painful dogs. A trial in client-owned dogs with radiographically confirmed osteoarthritis may be clinically relevant, yet still have limited transferability if the sample is small, the product is proprietary, blinding is weak or follow-up is short. Breed, age, body condition, concurrent care and the joint affected may all change interpretation.

Species separation also works in the other direction. A dog-and-cat oral-health study can provide useful signals, but pooled results may conceal species-specific responses. A canine course should not borrow a feline warning, a human interaction table or a rodent mechanism without labelling the evidence source and the uncertainty created by transfer.

• Direct canine clinical evidence measures outcomes in dogs with the condition of interest.
• Canine pharmacokinetic evidence measures exposure in dogs but may not show benefit.
• Canine biomarker evidence measures biological change but may not show how a dog feels or functions.
• Human, other-species and laboratory evidence is indirect and should be described as such.
• Traditional evidence documents use or belief; regulatory evidence documents rules, not efficacy.

A map of the current canine evidence landscape

The canine botanical literature is uneven rather than empty. Mobility and osteoarthritis form the most developed botanical-related cluster. Cannabidiol products have been studied in several small trials and synthesized in systematic reviews. Boswellia and curcuminoids appear mainly in proprietary combinations or fortified diets. These studies support detailed lessons about product identity, owner outcomes, objective measures, bias and mixture attribution.

Other clusters are smaller but educationally valuable. Silybin-containing products have been studied through liver enzymes and liver-associated microRNA. Proprietary botanical mixtures have been tested in canine atopic dermatitis. Catechin-containing products have been examined for oral bacteria, halitosis, plaque and gingivitis. A defined Echinacea powder was reported in an uncontrolled respiratory study. Preliminary behavioural and ageing work remains closer to a research frontier.

This landscape does not justify a catalogue of “herbs for diseases.” It does support a serious foundations course in how botanicals are identified, made, studied and interpreted. The limitation becomes part of the subject: learners see why one preparation can produce a useful finding while a much broader plant claim remains unjustified.

From evidence grade to defensible sentence

The A-G ladder is not a ranking of good plants and bad plants. It classifies the evidence supporting one exact statement. Grade A requires multiple reasonably rigorous canine studies of comparable preparations, routes, populations and outcomes with broadly consistent findings. Grade B includes one credible trial, several small trials, mixed results, limited replication, major product specificity or important risk of bias. Grade C covers canine pharmacokinetic, biomarker, observational or safety findings without demonstrated clinical benefit.

Grades D through G make other evidence visible without disguising it as canine efficacy: indirect mechanistic or other-species evidence; historical context; official regulatory or safety guidance; and no reliable evidence located within the defined search. A monograph can carry several grades at once. Cannabidiol, for example, can have Grade B clinical evidence, Grade C pharmacokinetic or safety evidence and Grade F Canadian regulatory context.

Good writing follows the grade. “Limited canine research has examined…” is more informative than either “proven” or “there is no evidence.” The learner’s job is to state the finding, then the boundary: the product studied, the outcomes measured, the uncertainty and the reason the conclusion cannot travel farther.